Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study.

OBJECTIVES: Possible immunomodulatory effect of amantadine in patients treated in intensive care unit (ICU), mostly among patients with brain injuries or vascular diseases was observed in several studies. The potential antiviral effect of amantadine against SARS-CoV-2 was discarded in clinical trials; however, immunomodulatory potential was not studied. The aim of the study was to investigate the effect of immunomodulatory amantadine therapy on mortality in patients with respiratory insufficiency due to COVID-19 requiring mechanical ventilation in ICU. METHODS: Retrospective analysis of 241 cases of 141 (58.5%) receiving intravenous amantadine sulfate vs 100 (41.5%) controls on standard of care only was performed. RESULTS: Overall mortality was 72.6%, being notably lower among amantadine treated patients (59.5%, n = 84) compared with controls (91%, n = 91), P-value = 0.001. In multivariate models administration of amantadine was independently associated with lower mortality rate (hazard ratio: 0.220, CI: 0.146-0.333 P-value = 0.001). Furthermore, survival was improved in patients who received amantadine; late administration of amantadine after 5th day was independently associated with lower mortality (hazard ratio: 0.560, CI: 0.313-0.999, P-value = 0.050). CONCLUSION: In patients treated in ICU with severe respiratory failure, administration of amantadine is associated with lower mortality, which may be associated with the potential anti-inflammatory and immunomodulatory effects of this agent.

Improved survival in ICU in severe COVID-19 associated with amantadine use – retrospective study

Introduction Possible immunomodulatory effect of amantadine in patients treated in intensive care units (ICU), mostly among patients with brain injuries or vascular diseases was observed in several studies. Potential antiviral effect of amantadine against SARS CoV-2 was discarded in clinical trials, however immunomodulatory potential was not studied. Objectives: The aim of the study was to investigate the effect of immunomodulatory amantadine therapy on mortality in patients with respiratory insufficiency due to COVID-19 requiring mechanical ventilation in ICU. Patients and methods Retrospective analysis of 241 cases of 141 (58.5%) receiving intravenous amantadine sulfate vs. 100 (41.5%) controls on standard of care only was performed. Results Overall mortality was 72.6%, being notably lower among amantadine treated patients (59.5%, n=84) compared to controls (91%, n=91), p= 0.001. In multivariate models administration of amantadine was independently associated with lower mortality rate [HR: 0.220 (CI: 0.146 – 0.333), p = 0.001)]. Furthermore, survival was improved in patients who received amantadine late - administration of amantadine after 5th day was independently associated with lower mortality [HR: 0.560 (CI: 0.313 – 0.999), p = 0.050). Conclusions In patients treated in ICU with severe respiratory failure administration of amantadine associated with lower mortality, which may be associated with potential anti-inflammatory and immunomodulatory effects of this agent.

Nosocomial COVID-19 Infection and Severe COVID-19 Pneumonia in Patients Hospitalized for Alcoholic Liver Disease: A Case Report.

BACKGROUND COVID-19 is an infectious disease caused by SARS-CoV-2. It has spread rapidly through the world, endangering human life. The main target of COVID-19 is the lungs; however, it can involve other organs, including the liver. Patients with severe COVID-19 have an increased incidence of abnormal liver function, and patients with liver disorders are considered to be at a higher risk of severe COVID-19 infection. The mechanism of liver injury reported in 14% to 53% of COVID-19 patients is poorly recognized and several possibilities need to be considered (cytokine storm, direct viral action, hypoxia). The incidence of underlying liver comorbidities in patients with a COVID-19 infection ranges from 1% to 11%. CASE REPORT This is a report of 2 nosocomial COVID-19 infections and severe COVID-19 pneumonia in 2 patients who were hospitalized during treatment for alcoholic liver disease (ALD). Case 1 and case 2 were a 31-year-old woman and a 40-year-old woman, respectively, with decompensated ALD and symptoms of the COVID-19 infection. Both patients were transferred from another hospital to our hospital after confirmation of COVID-19 during their hospitalization. The course of the infection progressed rapidly in both patients with the development of multiple-organ failure and death over a short period. CONCLUSIONS There are no clear recommendations on the management of ALD in the COVID-19 pandemic. Alcoholic hepatitis may be a risk factor for severe COVID-19 and a poor outcome. A high percentage of nosocomial COVID-19 infections are observed; therefore, special precautions should be taken to minimize the risk of COVID-19 exposure.